RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07340398, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: women only

    Registered eligibility fields

  2. Stage I (T1cN0M0)

    Inclusion criterion 5

    Stage II (T1cN1M0, T2N0-1M0 or T3N0M0)

    Inclusion criterion 6

    Stage III (T2N2-3M0, T3N1-3M0, or T4N0-3M0)

    Inclusion criterion 7

  3. Known hypersensitivity to study drug components; history of immunodeficiency (HIV positive, active HCV, active hepatitis B, other congenital/acquired immunodeficiency) or prior organ transplantation.

    Exclusion criterion 9

  4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

    Inclusion criterion 2

  5. Hemoglobin ≥100 g/L

    Inclusion criterion 11

    Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L

    Inclusion criterion 12

    Platelet count ≥100 × 10⁹/L

    Inclusion criterion 13

    Total bilirubin ≤1.5 × ULN

    Inclusion criterion 15

    ALT and AST ≤1.5 × ULN; ALP ≤2.5 × ULN

    Inclusion criterion 16

    BUN and creatinine ≤1.5 × ULN

    Inclusion criterion 17

  6. Breast cancer not confirmed histologically.

    Exclusion criterion 4

    History of other malignancy within the past 5 years, except successfully treated cervical carcinoma in situ.

    Exclusion criterion 5

  7. Women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment and agree to use effective contraception during the study and for 8 weeks after the last dose.

    Inclusion criterion 19

    Pregnant or breastfeeding women, or women of childbearing potential who test positive at baseline or are unwilling to use effective contraception throughout the study.

    Exclusion criterion 15

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07340398, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 and ≤75 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • Primary tumor size >1 cm.
  • Histologically confirmed invasive breast cancer, clinically staged as:
  • Stage I (T1cN0M0)
  • Stage II (T1cN1M0, T2N0-1M0 or T3N0M0)
  • Stage III (T2N2-3M0, T3N1-3M0, or T4N0-3M0)
  • HER2-positive status: IHC 3+ or IHC 2+ with positive ISH.
  • Adequate major organ function:
  • Hematology (no transfusion or hematopoietic growth factors, e.g., G-CSF, within 14 days):
  • Hemoglobin ≥100 g/L
  • Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L
  • Platelet count ≥100 × 10⁹/L
  • Biochemistry:
  • Total bilirubin ≤1.5 × ULN
  • ALT and AST ≤1.5 × ULN; ALP ≤2.5 × ULN
  • BUN and creatinine ≤1.5 × ULN
  • Cardiac function: LVEF ≥55% by echocardiography
  • Women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment and agree to use effective contraception during the study and for 8 weeks after the last dose.
  • Voluntary written informed consent and willingness to comply with study procedures and follow-up.

Exclusion Criteria:

  • Prior anti-tumor therapy for breast cancer, including chemotherapy, radiotherapy, targeted therapy, or endocrine therapy.
  • Concurrent administration of any other anti-tumor treatment.
  • Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer.
  • Breast cancer not confirmed histologically.
  • History of other malignancy within the past 5 years, except successfully treated cervical carcinoma in situ.
  • Severe dysfunction of major organs (heart, liver, kidney).
  • Conditions affecting oral drug administration or absorption, e.g., inability to swallow, chronic diarrhea, or intestinal obstruction.
  • Participation in another investigational drug trial within 4 weeks prior to enrollment.
  • Known hypersensitivity to study drug components; history of immunodeficiency (HIV positive, active HCV, active hepatitis B, other congenital/acquired immunodeficiency) or prior organ transplantation.
  • History of clinically significant cardiac disease, including:
  • Arrhythmia requiring medication
  • Myocardial infarction
  • Heart failure
  • Other cardiac conditions deemed unsuitable for study participation by the investigator
  • Pregnant or breastfeeding women, or women of childbearing potential who test positive at baseline or are unwilling to use effective contraception throughout the study.
  • Any condition that, in the investigator's judgment, poses serious risk to patient safety or may interfere with study completion (e.g., uncontrolled severe hypertension, uncontrolled diabetes, active infection).
  • History of neurological or psychiatric disorders (e.g., epilepsy or dementia) or any other condition the investigator considers incompatible with study participation.

Quoted from ClinicalTrials.gov, NCT07340398, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07340398, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07340398